By: Frank Angst Kentucky Equine Medical Director Mary Scollay is advocating a multi-pronged approach to regulating and preventing improper use of bisphosphonates, which experts have linked to catastrophic breakdowns when used in young horses because they interrupt the bone remodeling process as horses train. Scollay presented the overview during the Kentucky Horse Racing Commission meeting
By: Bill Finley A meeting among industry stakeholders in the Mid-Atlantic region is scheduled for Thursday and a proposal for a partial ban of the controversial drug Bisphosphonate tops the agenda. Bisphosphonate has come under increased scrutiny since the rash of breakdowns began at Santa Anita and some are speculating that its use might have
By: Frank Angst The Kentucky Horse Racing Commission has approved $147,000 from the Kentucky Equine Drug Research Council fund for a two-year study that aims to develop an affordable test to detect horses that have been given small levels—microdoses—of erythropoietin. Heather Knych, of the Ken L. Maddy Equine Analytical Chemistry Laboratory at the University of
By: Frank Angst Citing new research that suggests the metabolite of Dextromethorphan, Dextrorphan, can stay in a horse's system at a wider variance of time than previously realized, the Kentucky Horse Racing Commission earlier this year dropped sanctions in three cases where the metabolite was discovered. KHRC equine medical director Mary Scollay offered a presentation
By: Frank Angst After an in-depth review of its racing medication rules relative to the Association of Racing Commissioners International’s recommendations, a Kentucky council is recommending penalty classification changes for a pair of medications. The Kentucky Equine Drug Research Council recommended Feb. 1 that the expectorant ambroxol (Ambril) be moved to a more severe penalty
Press release AAEP Announces Initiative to Enhance Horse Health, Racing Integrity Prescription for Racing Reform to seek non-race day EIPH treatments, support 48-hour NSAID rule The American Association of Equine Practitioners today announced a multi-part initiative to protect the health and welfare of the racehorse and help ensure the long-term viability of the racing industry
By Frank Angst Through the first 10 months of 2014, U.S. horse racing appeared on pace to register its fewest positive drug tests for anabolic steroids since the industry moved to outlaw the drugs from racing in 2008-09. But six positives for the anabolic steroid stanozolol from Nov. 19 to Dec. 19 at Laurel Park
SIGN UP TO RECEIVE RMTC COMMUNICATIONS
Quick Links
Sign up to receive RMTC communications:
Sign up to receive RMTC communications:
